TROV Stock Soars 22% on Positive Mid-Stage Data at ESMO

TROV stock

TROV stock is one of the biggest biotech stock gainers this morning after TrovaGene Inc (NASDAQ:TROV) reported positive results from its Phase 1b/2 study of onvansertib.

Key Details

Companies in the therapeutics space strive for producing treatments for some of the most difficult health conditions in people, and any positive development about products in the pipeline is always welcome. Clinical stage oncology therapeutics company TrovaGene today made a major announcement with regards to its medicine that is meant for the treatment of relapsed/refractory acute myeloid leukemia (AML)—and the news has helped TROV stock.

The ...

Read The Full Article On

Get early insight on hidden secret gems on MicroSmallCap. Follow Crypto, Mining, Cannabis and Energy stocks and get free research reports here.

All content provided by MicroSmallCap is subject to our Terms Of Use and Disclaimer.

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.